Maria Jose Moreno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Jose Moreno has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Felipe Buitrago
Pontificia Universidad Javeriana, Bogotá, Cundinamarca Colombia
5 shared publications - Deissy Milena Garcia
Pontificia Universidad Javeriana, Bogotá, Cundinamarca Colombia
5 shared publications - Diana Matallana
Neuroscience Program, Aging Institute, Psychiatry Department, School of Medicine, Pontificia Universidad Javeriana, Bogotá 110231, Colombia
5 shared publications Laura Valentina Forero
Pontificia Universidad Javeriana, Bogotá, Cundinamarca Colombia
5 shared publications- Pablo Reyes
Pontificia Universidad Javeriana. PhD Program of Neuroscience. Laboratory of Cognition, Neuroscience and Context, Bogotá, Colombia
5 shared publications Carlos Rivera
Pontificia Universidad Javeriana, Bogotá, Cundinamarca Colombia
3 shared publications
Latest Publications
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Comparison between verbal and visual working memory in subjects with frontotemporal dementia and Alzheimer’s participating in the Redlat study
Background: Alterations in working memory have been reported in people with Alzheimer’s disease and frontotemporal degeneration, and have been associated with executive impairment related to the frontal areas of the brain.Method: The objective of this work is to compare the capacity of verbal and visual working memory in a sample of 70 Colombian people with dementia (32 with Alzheimer’s Dementia and 30 with Frontotemporal Dementia and 22 healthy controls) participating in the RedLat study. For this, the performance in a digit retention task and the Short Term Memory Binding Test (STMB) are studied.Result: In general, there is a decrease in the performance of the two groups of patients (AD and FTD). Also AD patients shows worst performance at visual working memory tasks. Results shows differences between dementia groups and controls, but not between AD and FTD.Conclusion: This converges with what has been reported about the dissociation between verbal and visual working memory, and could suggest alternative strategies for the recall of immediate information. Additionally, both low performances are explained by differents reasons in each neurodegenerative disorder.References:Stopford, C. L., Thompson, J. C., Neary, D., Richardson, A. M., & Snowden, J. S. (2012). Working memory, attention, and executive function in Alzheimer’s disease and frontotemporal dementia. Cortex, 48(4), 429‐446.Giovannetti, T., Lamar, M., Cloud, B. S., Swenson, R., Fein, D., Kaplan, E., & Libon, D. J. (2001). Different underlying mechanisms for deficits in concept formation in dementia. Archives of Clinical Neuropsychology, 16(6), 547‐560.Della Sala, S., Parra, M. A., Fabi, K., Luzzi, S., & Abrahams, S. (2012). Short‐term memory binding is impaired in AD but not in non‐AD dementias. Neuropsychologia, 50(5), 833‐840.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Open AccessComparison between verbal and visual working memory in subjects with frontotemporal dementia and Alzheimer’s participating in the Redlat study
Background: Alterations in working memory have been reported in people with Alzheimer’s disease and frontotemporal degeneration, and have been associated with executive impairment related to the frontal areas of the brain.Method: The objective of this work is to compare the capacity of verbal and visual working memory in a sample of 70 Colombian people with dementia (32 with Alzheimer’s Dementia and 30 with Frontotemporal Dementia and 22 healthy controls) participating in the RedLat study. For this, the performance in a digit retention task and the Short Term Memory Binding Test (STMB) are studied.Result: In general, there is a decrease in the performance of the two groups of patients (AD and FTD). Also AD patients shows worst performance at visual working memory tasks. Results shows differences between dementia groups and controls, but not between AD and FTD.Conclusion: This converges with what has been reported about the dissociation between verbal and visual working memory, and could suggest alternative strategies for the recall of immediate information. Additionally, both low performances are explained by differents reasons in each neurodegenerative disorder.References:Stopford, C. L., Thompson, J. C., Neary, D., Richardson, A. M., & Snowden, J. S. (2012). Working memory, attention, and executive function in Alzheimer’s disease and frontotemporal dementia. Cortex, 48(4), 429‐446.Giovannetti, T., Lamar, M., Cloud, B. S., Swenson, R., Fein, D., Kaplan, E., & Libon, D. J. (2001). Different underlying mechanisms for deficits in concept formation in dementia. Archives of Clinical Neuropsychology, 16(6), 547‐560.Della Sala, S., Parra, M. A., Fabi, K., Luzzi, S., & Abrahams, S. (2012). Short‐term memory binding is impaired in AD but not in non‐AD dementias. Neuropsychologia, 50(5), 833‐840.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Neuropsychological Characteristics of Posterior Cortical Atrophy: A Case Series Study in Participants of the RedLat Study
Background: Posterior cortical atrophy is a neurodegenerative condition characterized by the deterioration of visuospatial skills, associated with the deterioration in the occipital and parietal regions of the brain, and frequently associated with the neuropathology of Alzheimer’s disease.Method: The objective of this study is to describe the neuropsychological characteristics in a sample of five RedLat study participants diagnosed with this condition. The subjects were evaluated in cognitive areas of language, attention, memory, executive functions, and visuospatial skills with a series of neuropsychological tests.Result: The obtained data is analyzed in a descriptive manner. The results support that alterations with visual and spatial predominance. However executive dysfunction and language alterations are present aswell.Conclusion: These findings support the understanding of posterior cortical atrophy as a heterogeneous clinical syndrome.References:Yong, K. X., Graff‐Radford, J., Ahmed, S., Chapleau, M., Ossenkoppele, R., Putcha, D., … & Harding, E. (2023). Diagnosis and management of posterior cortical atrophy. Current Treatment Options in Neurology, 1‐21.Schott, J. M., & Crutch, S. J. (2019). Posterior Cortical Atrophy. Continuum (Minneapolis, Minn.), 25(1), 52‐75. https://doi.org/10.1212/CON.0000000000000696 Carvajal Castrillón, J., Aguirre, D. C., & Lopera, F. (2010). Perfil clínico y cognitivo de la atrofia cortical posterior y sus diferencias con la enfermedad de Alzheimer esporádica tardía y familiar precoz. Acta Neurológica Colombiana, 26(2), 75‐86.Iacono, L. L., Sarotto, L., & Braccia, M. L. (2022). Atrofia cortical posterior: la “variante visual” de la enfermedad de Alzheimer. Oftalmología Clínica y Experimental, 15(2).
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Open AccessNeuropsychological Characteristics of Posterior Cortical Atrophy: A Case Series Study in Participants of the RedLat Study
Background: Posterior cortical atrophy is a neurodegenerative condition characterized by the deterioration of visuospatial skills, associated with the deterioration in the occipital and parietal regions of the brain, and frequently associated with the neuropathology of Alzheimer’s disease.Method: The objective of this study is to describe the neuropsychological characteristics in a sample of five RedLat study participants diagnosed with this condition. The subjects were evaluated in cognitive areas of language, attention, memory, executive functions, and visuospatial skills with a series of neuropsychological tests.Result: The obtained data is analyzed in a descriptive manner. The results support that alterations with visual and spatial predominance. However executive dysfunction and language alterations are present aswell.Conclusion: These findings support the understanding of posterior cortical atrophy as a heterogeneous clinical syndrome.References:Yong, K. X., Graff‐Radford, J., Ahmed, S., Chapleau, M., Ossenkoppele, R., Putcha, D., … & Harding, E. (2023). Diagnosis and management of posterior cortical atrophy. Current Treatment Options in Neurology, 1‐21.Schott, J. M., & Crutch, S. J. (2019). Posterior Cortical Atrophy. Continuum (Minneapolis, Minn.), 25(1), 52‐75. https://doi.org/10.1212/CON.0000000000000696 Carvajal Castrillón, J., Aguirre, D. C., & Lopera, F. (2010). Perfil clínico y cognitivo de la atrofia cortical posterior y sus diferencias con la enfermedad de Alzheimer esporádica tardía y familiar precoz. Acta Neurológica Colombiana, 26(2), 75‐86.Iacono, L. L., Sarotto, L., & Braccia, M. L. (2022). Atrofia cortical posterior: la “variante visual” de la enfermedad de Alzheimer. Oftalmología Clínica y Experimental, 15(2).
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Facial emotional recognition in patients with dementia, part of the ReDLat study
Background: The social domain impairments associated with Alzheimer’s disease and frontotemporal lobar degeneration have been linked to basic neurocognitive processes such as visual emotion identification through facial expressions.Method: In this study, we explore the recognition of seven basic emotions presented in the Mini‐SEA test in a sample of 84 Colombian individuals with dementia (32 with Alzheimer’s Disease and 30 with Frontotemporal Dementia) and compare it with 22 healthy participants from the RedLat study.Result: The results of the behavioral performance show a lower performance in people with dementia compared to healthy subjects, however, no significant differences are reported between the patient group (AD and FTD).Conclusion: These findings may be associated with the clinical heterogeneity of the evaluated subjects.References:Couto, B., Manes, F., Montañés, P., Matallana, D., Reyes, P., Velasquez, M., … Ibáñez, A. (2013). Structural neuroimaging of social cognition in progressive non‐fluent aphasia and behavioral variant of frontotemporal dementia. Frontiers in Human Neuroscience, 7. https://doi.org/10.3389/fnhum.2013.00467 Hot, P., Klein‐Koerkamp, Y., Borg, C., Richard‐Mornas, A., Zsoldos, I., Paignon Adeline, A., … Baciu, M. (2013). Fear recognition impairment in early‐stage Alzheimer’s disease: When focusing on the eyes region improves performance. Brain and Cognition, 82(1), 25‐34. https://doi.org/10.1016/j.bandc.2013.02.001
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Open AccessFacial emotional recognition in patients with dementia, part of the ReDLat study
Background: The social domain impairments associated with Alzheimer’s disease and frontotemporal lobar degeneration have been linked to basic neurocognitive processes such as visual emotion identification through facial expressions.Method: In this study, we explore the recognition of seven basic emotions presented in the Mini‐SEA test in a sample of 84 Colombian individuals with dementia (32 with Alzheimer’s Disease and 30 with Frontotemporal Dementia) and compare it with 22 healthy participants from the RedLat study.Result: The results of the behavioral performance show a lower performance in people with dementia compared to healthy subjects, however, no significant differences are reported between the patient group (AD and FTD).Conclusion: These findings may be associated with the clinical heterogeneity of the evaluated subjects.References:Couto, B., Manes, F., Montañés, P., Matallana, D., Reyes, P., Velasquez, M., … Ibáñez, A. (2013). Structural neuroimaging of social cognition in progressive non‐fluent aphasia and behavioral variant of frontotemporal dementia. Frontiers in Human Neuroscience, 7. https://doi.org/10.3389/fnhum.2013.00467 Hot, P., Klein‐Koerkamp, Y., Borg, C., Richard‐Mornas, A., Zsoldos, I., Paignon Adeline, A., … Baciu, M. (2013). Fear recognition impairment in early‐stage Alzheimer’s disease: When focusing on the eyes region improves performance. Brain and Cognition, 82(1), 25‐34. https://doi.org/10.1016/j.bandc.2013.02.001
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
¿Frontotemporal dementia or Alzheimer’s disease? Phenotypic variability in a large family with neurodegenerative disorders
Background: The frontal variant of Alzheimer’s disease is characterized by behavioral changes and executive deficits in the early stages. This phenotype is similar in the behavioral variant of frontotemporal dementia, hindering the clinical diagnosis. The aim of this study is to describe the profile of cognitive, behavioral and motor disorders in a family with an autosomal dominant inheritance pattern of early‐onset dementia.Method: Five cases of affected individuals of a Colombian family are presented. We conducted an interdisciplinary clinical evaluation involving different specialties including geriatric, neurology, psychiatry, neuropsychology, and genetics. After each individual evaluation, a consensus was reached among the specialists to define the diagnosis.Result: In all cases, reported age of onset was before 60 years old. Three out of four cases met criteria for severe dementia and the remaining case presented Mild Cognitive Impairment (MCI). In two cases, the first symptoms reported were memory and planification problems that affected daily life activities. Nevertheless, at the formal evaluation, predominant changes at the executive functions and social cognition were found. In the other two cases, given the severity of the alterations, the evaluation was limited to the analysis of the clinical history, and it is suspected to be cases of linguistic variants of FTD.Conclusion: Intrafamilial phenotypic variability was described in this family. This variability in the presentation of the disease phenotype could guide the clinical diagnosis.References:Ossenkoppele, R., Singleton, E. H., Groot, C., Dijkstra, A. A., Eikelboom, W. S., Seeley, W. W., … & Pijnenburg, Y. A. (2022). Research criteria for the behavioral variant of Alzheimer disease: a systematic review and meta‐analysis. JAMA neurology, 79(1), 48‐60.Musa, G., Slachevsky, A., Muñoz‐Neira, C., Méndez‐Orellana, C., Villagra, R., González‐Billault, C., … & Lillo, P. (2020). Alzheimer’s disease or behavioral variant frontotemporal dementia? Review of key points toward an accurate clinical and neuropsychological diagnosis. Journal of Alzheimer’s disease, 73(3), 833‐848.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Open Access¿Frontotemporal dementia or Alzheimer’s disease? Phenotypic variability in a large family with neurodegenerative disorders
Background: The frontal variant of Alzheimer’s disease is characterized by behavioral changes and executive deficits in the early stages. This phenotype is similar in the behavioral variant of frontotemporal dementia, hindering the clinical diagnosis. The aim of this study is to describe the profile of cognitive, behavioral and motor disorders in a family with an autosomal dominant inheritance pattern of early‐onset dementia.Method: Five cases of affected individuals of a Colombian family are presented. We conducted an interdisciplinary clinical evaluation involving different specialties including geriatric, neurology, psychiatry, neuropsychology, and genetics. After each individual evaluation, a consensus was reached among the specialists to define the diagnosis.Result: In all cases, reported age of onset was before 60 years old. Three out of four cases met criteria for severe dementia and the remaining case presented Mild Cognitive Impairment (MCI). In two cases, the first symptoms reported were memory and planification problems that affected daily life activities. Nevertheless, at the formal evaluation, predominant changes at the executive functions and social cognition were found. In the other two cases, given the severity of the alterations, the evaluation was limited to the analysis of the clinical history, and it is suspected to be cases of linguistic variants of FTD.Conclusion: Intrafamilial phenotypic variability was described in this family. This variability in the presentation of the disease phenotype could guide the clinical diagnosis.References:Ossenkoppele, R., Singleton, E. H., Groot, C., Dijkstra, A. A., Eikelboom, W. S., Seeley, W. W., … & Pijnenburg, Y. A. (2022). Research criteria for the behavioral variant of Alzheimer disease: a systematic review and meta‐analysis. JAMA neurology, 79(1), 48‐60.Musa, G., Slachevsky, A., Muñoz‐Neira, C., Méndez‐Orellana, C., Villagra, R., González‐Billault, C., … & Lillo, P. (2020). Alzheimer’s disease or behavioral variant frontotemporal dementia? Review of key points toward an accurate clinical and neuropsychological diagnosis. Journal of Alzheimer’s disease, 73(3), 833‐848.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Social determinants of health in Colombian patients with Alzheimer Disease and Frontotemporal Dementia
Background: There are a series of social, economic, political, and cultural determinants that may impact the course of dementia. Previous studies have found that structural determinants are particularly important as they establish a set of hierarchies derived from socio‐economic position that determine institutional responses in both health and social services, which affect the health outcomes of everyone.Method: This presentation aims to characterize the socio‐economic factors in a sample of 70 Colombian individuals with dementia (35 with Alzheimer’s Disease and 35 with Frontotemporal Dementia) who participated in the RedLat project. Cluster analysis is proposed for a set of variables that are linked to the socio‐economic determinants of health that are queried from each participant in the framework of the RedLat project, and relates them to the disease progression time, severity, and impact on each person’s functionality.Result: Overall, it is found that the socio‐economic factors of each individual impact the course of the disease.Conclusion: These findings justify the need to implement public health programs that address the needs of and improve the living conditions of older adults.References:Buitrago, A. F. S., Perdomo, D. C., & Bogota, M. A. M. (2022). Asociación entre el deterioro cognitivo y factores socioeconómicos y sociodemográficos en adultos mayores colombianos. Revista Colombiana de Psiquiatría.Duran‐Aniotz, C., Sanhueza, J., Grinberg, L. T., Slachevsky, A., Valcour, V., Robertson, I., … & Ibáñez, A. (2022). The Latin American Brain Health Institute, a regional initiative to reduce the scale and impact of dementia.Hersi, M., Irvine, B., Gupta, P., Gomes, J., Birkett, N., & Krewski, D. (2017). Risk factors associated with the onset and progression of Alzheimer’s disease: A systematic review of the evidence. Neurotoxicology, 61, 143‐187.Parra, M. A., Baez, S., Sedeño, L., Gonzalez Campo, C., Santamaría‐García, H., Aprahamian, I., … & Ibanez, A. (2021). Dementia in Latin America: paving the way toward a regional action plan. Alzheimer’s & Dementia, 17(2), 295‐313.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Open AccessSocial determinants of health in Colombian patients with Alzheimer Disease and Frontotemporal Dementia
Background: There are a series of social, economic, political, and cultural determinants that may impact the course of dementia. Previous studies have found that structural determinants are particularly important as they establish a set of hierarchies derived from socio‐economic position that determine institutional responses in both health and social services, which affect the health outcomes of everyone.Method: This presentation aims to characterize the socio‐economic factors in a sample of 70 Colombian individuals with dementia (35 with Alzheimer’s Disease and 35 with Frontotemporal Dementia) who participated in the RedLat project. Cluster analysis is proposed for a set of variables that are linked to the socio‐economic determinants of health that are queried from each participant in the framework of the RedLat project, and relates them to the disease progression time, severity, and impact on each person’s functionality.Result: Overall, it is found that the socio‐economic factors of each individual impact the course of the disease.Conclusion: These findings justify the need to implement public health programs that address the needs of and improve the living conditions of older adults.References:Buitrago, A. F. S., Perdomo, D. C., & Bogota, M. A. M. (2022). Asociación entre el deterioro cognitivo y factores socioeconómicos y sociodemográficos en adultos mayores colombianos. Revista Colombiana de Psiquiatría.Duran‐Aniotz, C., Sanhueza, J., Grinberg, L. T., Slachevsky, A., Valcour, V., Robertson, I., … & Ibáñez, A. (2022). The Latin American Brain Health Institute, a regional initiative to reduce the scale and impact of dementia.Hersi, M., Irvine, B., Gupta, P., Gomes, J., Birkett, N., & Krewski, D. (2017). Risk factors associated with the onset and progression of Alzheimer’s disease: A systematic review of the evidence. Neurotoxicology, 61, 143‐187.Parra, M. A., Baez, S., Sedeño, L., Gonzalez Campo, C., Santamaría‐García, H., Aprahamian, I., … & Ibanez, A. (2021). Dementia in Latin America: paving the way toward a regional action plan. Alzheimer’s & Dementia, 17(2), 295‐313.
- Open Access
- 2 April 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (4) , e0230846
Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
The objective of this study was to characterize the demographic and clinical profile of RRMS patients receiving fingolimod in Spain, and to evaluate drug effectiveness and safety in clinical practice. This observational, retrospective, multicentre, nationwide study was performed at 56 Spanish hospitals and involved 804 RRMS patients who received oral fingolimod (0.5 mg) since November 2011, with a minimum follow-up of 12 months. The mean annualized relapse rate (ARR) in the year before fingolimod was 1.08 and the median EDSS was 3; patients were exposed to fingolimod for 2.2 years as average; regarding magnetic resonance imaging (MRI) activity, more than half of the patients had >20 lesions at baseline. Patients were previously treated with first-line injectable DMTs (60.3%), or natalizumab (31.3%), and 8.3% were naïve patients. Overall, the ARR significantly decreased to 0.28, 0.22 and 0.17 (74.1%, 79.7% and 83.5% of relative reduction, respectively) after 12, 24 and 36 months of treatment, P<0.001. The ARR of patients who switched from natalizumab to fingolimod was stable over the study. Most of the patients (88.7%) were free from confirmed disability and MRI activity (67.3%) after 24 months. The persistence after 12 months on fingolimod was 93.9%. The subgroups of patients analysed showed differential baseline demographic and clinical characteristics. The analysis of patients who received fingolimod in routine clinical practice confirmed adequate efficacy and safety, even for long-term treatment. The present data also confirmed the positive benefit/risk balance with fingolimod in real-world clinical practice setting.
- 2 April 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (4) , e0230846
Open AccessSpanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
The objective of this study was to characterize the demographic and clinical profile of RRMS patients receiving fingolimod in Spain, and to evaluate drug effectiveness and safety in clinical practice. This observational, retrospective, multicentre, nationwide study was performed at 56 Spanish hospitals and involved 804 RRMS patients who received oral fingolimod (0.5 mg) since November 2011, with a minimum follow-up of 12 months. The mean annualized relapse rate (ARR) in the year before fingolimod was 1.08 and the median EDSS was 3; patients were exposed to fingolimod for 2.2 years as average; regarding magnetic resonance imaging (MRI) activity, more than half of the patients had >20 lesions at baseline. Patients were previously treated with first-line injectable DMTs (60.3%), or natalizumab (31.3%), and 8.3% were naïve patients. Overall, the ARR significantly decreased to 0.28, 0.22 and 0.17 (74.1%, 79.7% and 83.5% of relative reduction, respectively) after 12, 24 and 36 months of treatment, P<0.001. The ARR of patients who switched from natalizumab to fingolimod was stable over the study. Most of the patients (88.7%) were free from confirmed disability and MRI activity (67.3%) after 24 months. The persistence after 12 months on fingolimod was 93.9%. The subgroups of patients analysed showed differential baseline demographic and clinical characteristics. The analysis of patients who received fingolimod in routine clinical practice confirmed adequate efficacy and safety, even for long-term treatment. The present data also confirmed the positive benefit/risk balance with fingolimod in real-world clinical practice setting.